Global Subcutaneous Nucleic Acid Therapeutics Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Subcutaneous Nucleic Acid Therapeutics Market Size

• The global subcutaneous nucleic acid therapeutics market size was valued at USD 2.88 billion in 2024 and is expected to reach USD 5.02 billion by 2032, at a CAGR of 7.20% during the forecast period
• The market expansion is primarily driven by advancements in RNA-based therapies and gene-modifying technologies, enhancing the delivery and efficacy of treatments administered via the subcutaneous route
• In addition, increasing prevalence of genetic and chronic disorders, combined with the rising preference for self-administered and patient-friendly therapeutic options, is reinforcing the shift toward subcutaneous delivery. These combined dynamics are accelerating demand and innovation in this segment, substantially contributing to overall market growth

Subcutaneous Nucleic Acid Therapeutics Market Analysis

• Subcutaneous nucleic acid therapeutics, involving the administration of RNA- and DNA-based drugs via the subcutaneous route, are emerging as a preferred modality in modern precision medicine due to their improved patient compliance, reduced need for clinical visits, and compatibility with self-administration technologies
• The accelerating demand for these therapeutics is largely driven by the increasing prevalence of genetic disorders, advancements in RNA interference and antisense oligonucleotide platforms, and a growing emphasis on minimally invasive treatment delivery
• North America dominated the subcutaneous nucleic acid therapeutics market with the largest revenue share of 46.1% in 2024, characterized by robust R&D investments, early adoption of genetic medicines, and regulatory support, with the U.S. seeing rapid clinical integration of subcutaneously administered RNA-based therapies for rare and chronic conditions
• Asia-Pacific is expected to be the fastest growing region in the subcutaneous nucleic acid therapeutics market during the forecast period due to expanding healthcare infrastructure, increased funding in genetic research, and rising patient awareness of innovative treatment options
• RNA Interference segment dominated the subcutaneous nucleic acid therapeutics market with a market share of 48.3% in 2024, driven by its successful commercialization of RNAi-based subcutaneous therapies and ongoing clinical advancements targeting a wide range of genetic and metabolic diseases

Report Scope and Subcutaneous Nucleic Acid Therapeutics Market Segmentation  

Subcutaneous Nucleic Acid Therapeutics Market Trends

“Patient-Centric Delivery Through Self-Administration Technologies”

• A significant and accelerating trend in the global subcutaneous nucleic acid therapeutics market is the growing adoption of self-administration technologies, which enable patients to receive RNA- and DNA-based treatments outside of clinical settings, enhancing treatment accessibility and adherence
  • For instance, therapies such as Amvuttra (vutrisiran) and Givlaari (givosiran) are designed for subcutaneous administration and allow patients with rare genetic conditions to manage their treatment at home using pre-filled syringes or auto-injectors, reducing dependence on infusion centers
• The integration of digital health tools with subcutaneous delivery systems is also on the rise, with smart injectors capable of tracking dosing schedules, monitoring adherence, and alerting healthcare providers in real-time. This is especially beneficial in chronic treatment scenarios where sustained patient engagement is critical
• Companies such as Alnylam Pharmaceuticals are pioneering this trend by developing next-generation RNAi therapeutics that combine subcutaneous delivery with simplified dosing regimens and improved patient usability
• The demand for patient-friendly, minimally invasive delivery platforms is growing rapidly across rare and chronic disease segments, as patients and providers asuch as prioritize convenience, autonomy, and long-term disease management outside of traditional clinical environments

Subcutaneous Nucleic Acid Therapeutics Market Dynamics

Driver

“Rising Demand for Targeted and Minimally Invasive Therapies”

• The growing prevalence of genetic, chronic, and rare diseases, coupled with the increasing demand for targeted therapies that minimize systemic side effects, is a key driver fueling the adoption of subcutaneous nucleic acid therapeutics
  • For instance, in January 2024, Alnylam Pharmaceuticals expanded access to its subcutaneously administered RNAi therapy, Amvuttra, for treating hereditary transthyretin-mediated amyloidosis, emphasizing patient convenience and reduced clinical burden. Such advancements highlight the shift toward subcutaneous delivery for complex genetic disorders
• As patients and healthcare systems prioritize less invasive, home-administered treatment options, subcutaneous delivery offers clear advantages over intravenous routes, including improved adherence, reduced hospital visits, and enhanced quality of life
• In addition, advancements in delivery technologies such as lipid nanoparticles and conjugate systems have significantly improved the stability, targeting efficiency, and bioavailability of nucleic acid therapeutics administered subcutaneously
• The broader trend toward personalized medicine and the integration of connected health technologies further enhances the appeal of subcutaneous nucleic acid therapies, supporting their adoption across a wide range of therapeutic areas in both high-income and emerging markets

Restraint/Challenge

“Skin Irritation Issues and Regulatory Compliance Hurdle”

• The occurrence of local skin reactions, such as erythema, pain, or swelling at the injection site, presents a notable challenge to the broader adoption of subcutaneous nucleic acid therapeutics. These side effects can impact patient comfort and adherence, particularly for therapies requiring frequent or long-term administration
  • For instance, clinical studies on RNAi and antisense oligonucleotide therapies such as givosiran and nusinersen have reported mild to moderate injection site reactions, raising concerns about patient tolerability in large-scale or chronic treatment settings
• Addressing these issues requires continuous innovation in formulation technologies and injection devices that minimize tissue irritation and improve delivery efficiency. Companies are exploring options such as lower-volume injections, slow-release formulations, and biocompatible carriers to reduce adverse reactions
• In parallel, the complex regulatory landscape for nucleic acid-based therapies remains a significant barrier, as agencies require stringent validation of safety, efficacy, and delivery mechanisms. The evolving nature of gene-modifying treatments poses challenges for standardized clinical trial frameworks and long-term safety assessment
• Navigating these hurdles through proactive collaboration with regulatory bodies, investing in post-market surveillance, and enhancing patient-centric drug design will be essential for ensuring sustained adoption and market expansion

Subcutaneous Nucleic Acid Therapeutics Market Scope

The market is segmented on the basis of product, application, and end user.

• By Product

On the basis of product, the subcutaneous nucleic acid therapeutics market is segmented into antisense oligonucleotides, RNA interference (RNAi), aptamers, gene therapy, nucleotide analogs, and others. The RNA interference (RNAi) segment held the largest market revenue share of 48.3% in 2024, driven by the successful commercialization of RNAi-based subcutaneous therapies such as Givlaari and Amvuttra, which target rare genetic conditions. RNAi therapies are known for their high specificity in gene silencing and are gaining momentum due to their efficacy and low dosing frequency.

The gene therapy segment is anticipated to witness the fastest CAGR from 2025 to 2032, supported by advances in delivery platforms and the growing pipeline of gene-editing treatments designed for subcutaneous administration. Gene therapies offer the potential for one-time, long-lasting treatment effects and are increasingly being explored for conditions requiring localized, minimally invasive delivery routes.

• By Application

On the basis of application, the market is segmented into genetic disorders, multigenic disorders, infectious diseases, neurological disorders, and cardiovascular disorders. The genetic disorders segment dominated the market in 2024, supported by a rising number of approved subcutaneous RNA-based drugs that target rare and inherited conditions such as hereditary transthyretin-mediated amyloidosis (hATTR). These therapies address unmet medical needs and are often eligible for accelerated regulatory pathways and orphan drug benefits.

The infectious diseases segment is projected to grow at the fastest CAGR during the forecast period, fueled by increasing research into nucleic acid vaccines and antiviral agents delivered subcutaneously. The success of mRNA vaccines has paved the way for broader exploration of subcutaneous delivery in combating viral infections and pandemic preparedness.

• By End User

On the basis of end user, the market is segmented into hospitals & clinics, academic & research institutes, and specialty centers. The hospitals & clinics segment held the largest market revenue share in 2024, owing to their role in administering approved therapies and managing chronic genetic conditions that require regular monitoring and support. These facilities also lead in conducting clinical trials and adopting new therapeutic innovations.

The specialty centers segment is expected to register the fastest growth from 2025 to 2032, driven by the rising demand for personalized medicine, home-based care services, and outpatient administration of advanced therapies. Specialty centers offer targeted, high-value care and are becoming essential hubs for administering self-injectable biologics and nucleic acid-based treatments.

Subcutaneous Nucleic Acid Therapeutics Market Regional Analysis

• North America dominated the subcutaneous nucleic acid therapeutics market with the largest revenue share of 46.1% in 2024, driven by robust R&D investments, early adoption of genetic medicines, and regulatory support
• Patients and providers in the region value the convenience, reduced clinical burden, and patient-friendly nature of subcutaneous delivery, especially for chronic and rare genetic conditions requiring regular dosing
• This widespread uptake is further bolstered by high healthcare expenditure, a growing focus on personalized medicine, and the presence of leading biotech companies actively developing and commercializing subcutaneous nucleic acid therapies, positioning the region as a global innovation hub for this treatment modality

U.S. Subcutaneous Nucleic Acid Therapeutics Market Insight

The U.S. subcutaneous nucleic acid therapeutics market captured the largest revenue share of 83% in 2024 within North America, driven by early adoption of RNA-based therapies and strong clinical infrastructure. Growing investment in precision medicine, increased FDA approvals of subcutaneously administered therapies, and expanding use in rare and chronic genetic disorders are propelling market growth. Furthermore, the shift toward home-based care and patient-centric treatment models, supported by widespread insurance coverage and healthcare innovation, is accelerating demand across the country.

Europe Subcutaneous Nucleic Acid Therapeutics Market Insight

The Europe subcutaneous nucleic acid therapeutics market is projected to grow at a substantial CAGR throughout the forecast period, supported by robust regulatory frameworks, expanding genomic research, and public health funding. Increased awareness of genetic disorders and strong clinical trial activity across Germany, France, and the U.K. are driving adoption. European healthcare systems are also favoring subcutaneous therapies due to reduced hospital load and improved patient compliance, with significant uptake across rare disease and chronic illness treatment pathways

U.K. Subcutaneous Nucleic Acid Therapeutics Market Insight

The U.K. subcutaneous nucleic acid therapeutics market is expected to grow at a noteworthy CAGR during the forecast period, driven by growing demand for minimally invasive treatments and a strong government focus on genomic medicine. National initiatives such as the Genomics England project are supporting early diagnosis and RNA/DNA-based therapeutic adoption. In addition, the NHS’s emphasis on outpatient care and personalized medicine is encouraging broader use of subcutaneously delivered therapies in both hospital and home settings.

Germany Subcutaneous Nucleic Acid Therapeutics Market Insight

The Germany subcutaneous nucleic acid therapeutics market is expected to expand at a considerable CAGR during the forecast period, backed by the country’s advanced biotech industry and support for innovative therapeutics. Germany’s strong clinical trial infrastructure, focus on sustainable healthcare delivery, and increasing demand for precision therapies are boosting the adoption of subcutaneous RNA and DNA-based treatments. Integration with digital health systems and preference for self-administered care options align with consumer and healthcare provider expectations.

Asia-Pacific Subcutaneous Nucleic Acid Therapeutics Market Insight

The Asia-Pacific subcutaneous nucleic acid therapeutics market is poised to grow at the fastest CAGR during the forecast period of 2025 to 2032, driven by improving healthcare infrastructure, expanding research capabilities, and rising prevalence of chronic and genetic diseases. Countries such as China, Japan, and India are investing in biopharmaceutical innovation and adopting RNA-based therapies through government-backed health programs and private sector collaboration. The rise in biotech manufacturing hubs is also enhancing the affordability and availability of subcutaneous formulations.

Japan Subcutaneous Nucleic Acid Therapeutics Market Insight

The Japan subcutaneous nucleic acid therapeutics market is gaining momentum due to the country's leadership in medical innovation, aging population, and focus on personalized care. Widespread use of RNAi-based therapies in rare disease management, combined with strong regulatory and academic collaboration, is driving growth. In addition, the adoption of home-based subcutaneous treatment options is aligned with Japan’s healthcare strategy to manage long-term illnesses in a cost-effective, patient-centered manner.

India Subcutaneous Nucleic Acid Therapeutics Market Insight

The India subcutaneous nucleic acid therapeutics market accounted for the largest market revenue share in Asia Pacific in 2024, propelled by rapid urbanization, increasing diagnosis of rare genetic disorders, and growing biotech investment. The Indian government’s support for genomics and digital health, along with the rise of local manufacturing capabilities, is improving access to subcutaneously delivered RNA/DNA therapies. Expanding middle-class healthcare demand and adoption of telemedicine and home-care services are further boosting market potential.

Subcutaneous Nucleic Acid Therapeutics Market Share

The subcutaneous nucleic acid therapeutics industry is primarily led by well-established companies, including:

• Alnylam Pharmaceuticals, Inc. (U.S.)
• Ionis Pharmaceuticals, Inc. (U.S.)
• Moderna, Inc. (U.S.)
• Silence Therapeutics plc (United Kingdom)
• Biogen Inc. (U.S.)
• Arrowhead Pharmaceuticals, Inc. (U.S.)
• Sarepta Therapeutics, Inc. (U.S.)
• Wave Life Sciences Ltd. (Singapore)
• Pfizer Inc. (U.S.)
• F. Hoffmann-La Roche (Switzerland)
• AstraZeneca (U. K.)
• Amgen Inc. (U.S.)
• Vertex Pharmaceuticals Incorporated (U.S.)
• BioNTech SE (Germany)
• Regeneron Pharmaceuticals, Inc. (U.S.)
• Sirnaomics, Inc. (U.S.)
• Lexeo Therapeutics, Inc. (U.S.)
• CureVac N.V. (Germany)
• Takeda Pharmaceutical Company Limited (Japan)

What are the Recent Developments in global subcutaneous nucleic acid therapeutics market?

• In April 2024, Alnylam Pharmaceuticals announced expanded global access to Amvuttra (vutrisiran), its RNA interference (RNAi) therapy administered via subcutaneous injection for hereditary transthyretin-mediated amyloidosis (hATTR). This move supports wider patient reach across North America, Europe, and Asia-Pacific and reflects the company’s focus on delivering convenient, long-acting genetic therapies with improved patient compliance. The initiative underscores Alnylam’s leadership in RNA therapeutics and the growing adoption of subcutaneous delivery in chronic rare disease treatment
• In March 2024, Ionis Pharmaceuticals reported positive results from Phase 3 trials of Tofersen, an antisense oligonucleotide therapy for SOD1-ALS, administered subcutaneously. The findings showed significant slowing of disease progression and better tolerability due to the subcutaneous route. This development marks a critical milestone in neurodegenerative disease management and reinforces the potential of self-administered nucleic acid drugs in complex indications
• In February 2024, Moderna, Inc. announced plans to expand its mRNA platform to include subcutaneously administered treatments targeting latent viral infections. The company’s pipeline now includes mRNA-based therapies for CMV and EBV, exploring alternative delivery routes beyond intramuscular injections. This move signals growing interest in subcutaneous administration for therapeutic mRNA beyond vaccines and represents a strategic pivot toward broader chronic disease applications
• In January 2024, Silence Therapeutics entered into a partnership with Hansoh Pharma to co-develop and commercialize SLN360, an siRNA therapy targeting elevated lipoprotein(a), in the Asia-Pacific region. The therapy is designed for subcutaneous delivery and addresses unmet needs in cardiovascular risk management. This collaboration highlights increasing cross-border investments in RNA-based therapies and the expanding role of subcutaneous modalities in managing widespread chronic diseases

SKU-74208